melinta_logo
melinta_sub_banner1
melinta_sub_banner2
melinta_sub_banner3
melinta_sub_banner4
melinta_sub_banner5
Video

Acute bacterial skin and skin structure infections are major reasons for hospitalizations in the United States, affecting millions of people annually










Zervos MJ et al, Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients. J Clin Microbiol 2012 Feb;50(2):238-45.

Agency for Healthcare Research and Quality, 2011 data (http://hcupnet.ahrq.gov/HCUPnet.jsp)
At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to combat them.

More than 23,000 people in the U.S. die each year from antibiotic-resistant infections. Many more die from conditions complicated by an antibiotic-resistant infection.










Source: U.S. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2013.

MRSA is the most common causative pathogen of hospital-treated acute bacterial skin and skin structure infections (ABSSSI).

It is estimated that MRSA kills more people each year than AIDS/HIV today or the polio epidemic at its peak.









Source: Zervos MJ et al, Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients. J. Clin Microbiol 2012 Feb;50(2):238-45.

Infectious Diseases Society of America Topics of Interest. Facts about Antibiotic Resistance. Revised April 2011. Accessed September 11, 2013 at http://goo.gl/q67UDP

ESKAPE pathogens are the six resistant bacteria that are among the most difficult to treat:


66% of all hospital infections are caused by ESKAPE pathogens.










Source: Rice LB. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: no ESKAPE. J. Infect. Dis.197(8), 1079-1081 (2008)
Press Releases and News
February 9, 2015
Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
January 8, 2015
Melinta Therapeutics and Eurofarma Laboratórios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil
January 7, 2015
Melinta Therapeutics’ Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI